GLOBAL IBS-C DRUG MARKET FORECAST 2020-2028

Inkwood Research estimates that the market for IBS-C drug will grow with an anticipated CAGR of 9.21% during the forecast period and will reach revenue of $23.49 billion by 2028. The base year considered for the market study is 2019, and the forecasted period is between 2020 and 2028.

The global IBS-C drug market growth is propelled by the following factors:

  • Modern dietary habits taking a toll on the health
  • IBS can be a heritability issue
  • Availability of effective drugs in the market

Diet management for a person with IBS involves a little extra time, but is often worth the effort. Poor dietary habits are one of the major reasons for irritable bowel syndrome. Dietary habits of people are changing, which is a major cause of IBS these days. Due to highly prevailing modern dietary habits, there is a rise in the number of people suffering from IBS. Some of the dietary habits leading to constipation are intake of foods such as insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and thus, urination of water can again lead to IBS.

Over the counter is the largest and the fastest-growing domain in the prescription type segment in the global IBS-C Drug market, with around 61.17% market share in 2019. OTC drugs are medications consumed without seeking treatment from doctors. There is a huge demand for over the counter drugs in the US, UK, France, Spain, Germany, China, India, and Indonesia. However, precautions must be taken before taking any such drugs. Side effects such as nausea, stomach pain, swelling of the face, tightness in throat, diarrhea, gas, vomiting, dry mouth, running nose, cough, fever, and headache, and so on may be caused. Several kinds of OTC laxatives are available in the market. OTC fiber products such as psyllium (brand name Metamucil), polycarbophil (FiberCon), and methylcellulose (Citrucel), are usually adopted for irritable bowel syndrome constipation. Moreover, another option is the milk of magnesia, which targets an upset stomach and constipation. These products work by stimulating the bowel. They generally take a few hours to take effect.

On the other hand, the global IBS-C drug market growth is restricted by strict FDA regulations, unawareness, and ignorance, among people. The industry suffers from strict regulations from the FDA, and other regulatory authorities, which leads to many of the drugs either called off from the market or not approved by the FDA. This is due to some serious after-effects of the drugs used to get rid of Irritable Bowel Syndrome. The number of drugs approved by the FDA is also very less in number, for example, Amitiza and Lotronex. Several drugs available in the market are either called back from the market or have a very restricted use under strict medical surveillance. This is due to the severe side effects shown by these drugs. Some of the drugs in the market even showed a lethal effect due to which they were called back. Due to these results, the FDA has made very strict rules to approve a drug that can be sold in the market, and this is acting as a very strong restraint for the market growth.

The report scope of the global IBS-C drug market covers segmentation analysis of prescription type and drug type.

Market by Prescription Type:

  • Prescribed
    • Branded
    • Generic
  • Over the Counter

Market by Drug Type:

  • Lubiprostone
  • Linaclotide
  • Stimulant Laxatives
    • Bisacodyl
    • Senna
  • Osmotic Laxatives
    • Lactulose
    • Polyethylene Glycol
  • Other Drug Types

Geographically, the global IBS-C drug market has been segmented into four major regions which include:

  • North America: the United States and Canada
  • Europe: the United Kingdom, France, Germany, Italy, Belgium, Poland, Russia, and the Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Thailand, Vietnam, Indonesia, Australia & New Zealand, and the rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

Geographically, North America is the largest market with a market share of 43.58% in terms of revenue in 2019. The dominance of North America is attributed to the government initiatives to improve the healthcare segment of the society by providing the latest technologies and advance medication treatment support. Federal agencies and private medical firms in this region together participate in giving access to the worlds best medical facilities for patients from all corners of the world. The Asia Pacific, on the other hand, is anticipated to be the fastest-growing region with a CAGR of 9.96% during the forecast period. Growing lifestyle-oriented diseases, an increase in healthcare spending, an increasing number of patients suffering from depression (anxiety and stress), severe gastrointestinal infection, and medical advancement in the field are the important causes that have led to the growth of the irritable bowel syndrome (IBS) drug market. The region consists of countries with a large population, and several countries have an innovative healthcare system.

Some of the major players in the global IBS-C drug market include:

  • Catalent Pharmaceuticals Solutions
  • Abbott Laboratories
  • Novartis Pharma AG
  • Ono Pharmaceutical Co. Ltd.
  • Actavis Nordic A/S
  • Others

In September 2018, Ardelyx submitted NDA to theU.S. FDA requesting the marketing authorization of Tenapanor to treat patients with IBS-C. In September 2019, Synthetic Biologics, Inc. announced the U.S. Patent and Trademark Office U.S. Patent and Trademark Office granted a US patent for SYN-010.

Key findings of the global IBS-C drug market include:

  • North America leads the global IBS-C Drug market by capturing the largest market share of around 43.58% in 2019.
  • Asia Pacific IBS-C Drug market is anticipated to grow at the highest CAGR of 9.96% during the forecast period of 2020-2028.
  • Psychological factors are affecting irritable bowel syndrome.
  • Change in lifestyle and natural ways is one of the many ways prescribed to cure irritable bowel syndrome.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1. MARKET DEFINITION
    2. KEY DRIVERS
      1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
      2. IBS CAN BE A HERITABILITY ISSUE
      3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
    3. KEY RESTRAINTS
      1. STRICT FDA REGULATIONS
      2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
  4. KEY ANALYTICS
    1. KEY INVESTMENT INSIGHTS
    2. PORTERS FIVE FORCE ANALYSIS
      1. BUYER POWER
      2. SUPPLIER POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. REGULATORY FRAMEWORK
  5. MARKET BY PRESCRIPTION TYPE
    1. PRESCRIBED
      1. BRANDED
      2. GENERIC
    2. OVER THE COUNTER
  6. MARKET BY DRUG TYPE
    1. LUBIPROSTONE
    2. LINACLOTIDE
    3. STIMULANT LAXATIVES
      1. BISACODYL
      2. SENNA
    4. OSMOTIC LAXATIVES
      1. LACTULOSE
      2. POLYETHYLENE GLYCOL
    5. OTHER DRUG TYPES
  7. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. UNITED STATES
      2. CANADA
    2. EUROPE
      1. UNITED KINGDOM
      2. GERMANY
      3. FRANCE
      4. ITALY
      5. RUSSIA
      6. BELGIUM
      7. POLAND
      8. REST OF EUROPE
    3. ASIA PACIFIC
      1. CHINA
      2. JAPAN
      3. INDIA
      4. SOUTH KOREA
      5. INDONESIA
      6. THAILAND
      7. VIETNAM
      8. AUSTRALIA & NEW ZEALAND
      9. REST OF ASIA PACIFIC
    4. REST OF WORLD
      1. LATIN AMERICA
      2. MIDDLE EAST & AFRICA
  8. COMPANY PROFILES
    1. CATALENT PHARMACEUTICALS SOLUTIONS
    2. ABBOTT LABORATORIES
    3. NOVARTIS PHARMA AG
    4. ASTELLAS PHARMACEUTICALS
    5. ARDELYX, INC.
    6. SYNTHETIC BIOLOGICS, INC.
    7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    8. BAMA-GEVE, SLU
    9. FERRING BV
    10. IRONWOOD PHARMACEUTICALS, INC.
    11. SALIX PHARMACEUTICALS LTD.
    12. NORGINE B.V.
    13. PROMETHEUS LABORATORIES, INC.
    14. ALBIREO PHARMA, INC.
    15. YUHAN CORP.
    16. ASTRAZENECA PLC
    17. THE MENARINI GROUP
    18. ONO PHARMACEUTICAL CO. LTD.
    19. ACTAVIS NORDIC A/S

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT IBS-C DRUG

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 5: GLOBAL PRESCRIBED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: GLOBAL PRESCRIBED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 7: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 9: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 10: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 12: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 13: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 14: GLOBAL OVER THE COUNTER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 15: GLOBAL OVER THE COUNTER MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 18: PRODUCT PROFILE (LUBIPROSTONE)

TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 21: PRODUCT PROFILE (LINACLOTIDE)

TABLE 22: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 23: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 24: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 25: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 26: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 27: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 28: PRODUCT PROFILE (BISACODYL)

TABLE 29: GLOBAL BISACODYLMARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 30: GLOBAL BISACODYLMARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 31: PRODUCT PROFILE (SENNA)

TABLE 32: GLOBAL SENNA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 33: GLOBAL SENNA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 34: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 35: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 36: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 37: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 38: PRODUCT PROFILE (LACTULOSE)

TABLE 39: GLOBAL LACTULOSE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 40: GLOBAL LACTULOSE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 41: PRODUCT PROFILE (POLYETHYLENE GLYCOL)

TABLE 42: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 43: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 44: PRODUCT PROFILE (PSYLLIUM)

TABLE 45: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 46: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 47: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 48: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 49: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 50: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 51: EUROPE IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 52: EUROPE IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 53: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 54: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 55: REST OF WORLD IBS-C DRUG MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 56: REST OF WORLD IBS-C DRUG MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: DRUGS PULLED OFF FROM THE MARKET

FIGURE 2: KEY INVESTMENT INSIGHTS

FIGURE 3: PORTERS FIVE FORCE ANALYSIS

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019

FIGURE 7: GLOBAL IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)

FIGURE 8: GLOBAL IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)

FIGURE 9: GLOBAL IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)

FIGURE 10: GLOBAL IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)

FIGURE 11: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019

FIGURE 12: GLOBAL IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)

FIGURE 13: GLOBAL IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)

FIGURE 14: GLOBAL IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)

FIGURE 15: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

FIGURE 16: GLOBAL IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)

FIGURE 17: GLOBAL IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)

FIGURE 18: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

FIGURE 19: GLOBAL IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)

FIGURE 20: GLOBAL IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)

FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 24: EUROPE IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 25: UNITED KINGDOM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 26: GERMANY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 27: FRANCE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 28: ITALY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 29: RUSSIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 30: BELGIUM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 31: POLAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 32: REST OF EUROPE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 33: ASIA PACIFIC IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 34: CHINA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 35: CHINESE MEDICINE TCM TREATMENT FOR IBS

FIGURE 36: JAPAN IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 37: INDIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 38: SOUTH KOREA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 39: INDONESIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 40: THAILAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 41: VIETNAM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 42: AUSTRALIA & NEW ZEALAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 43: REST OF ASIA PACIFIC IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 44: REST OF WORLD IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 45: LATIN AMERICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

FIGURE 46: MIDDLE EAST & AFRICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

Request For A Free Sample